(VIANEWS) – Good morning! Another day of trading is almost starting and here’s today’s list of stocks that have had significant trading activity in the US premarket session.

The three most active and biggest winners today are Avery Dennison Corporation, Bio-Rad, and Broadridge Financial Solutions.

Rank Financial Asset Price Premarket
Change
Updated (EST)
1 Avery Dennison Corporation (AVY) 235.93 14.05% 2022-01-19 04:38:33
2 Bio-Rad (BIO) 675.39 12.6% 2022-01-19 04:39:02
3 Broadridge Financial Solutions (BR) 169.23 5.82% 2022-01-19 04:19:44
4 Yandex (YNDX) 51.50 5.77% 2022-01-19 07:30:33
5 Quidel (QDEL) 115.74 5.16% 2022-01-19 04:44:15
6 Unilever (UL) 48.54 4.5% 2022-01-19 04:47:28
7 Cloudflare (NET) 97.50 4.13% 2022-01-19 04:49:16
8 Pacific Biosciences of California (PACB) 11.56 3.96% 2022-01-19 07:28:41
9 Groupon (GRPN) 22.50 3.93% 2022-01-19 04:27:03
10 Canaan (CAN) 5.40 3.65% 2022-01-19 07:18:35

The three most active and biggest losers today are U.S. Bancorp, NeuroMetrix, and Moderna.

Rank Financial Asset Price Premarket
Change
Updated (EST)
1 U.S. Bancorp (USB) 59.42 -4.45% 2022-01-19 07:27:34
2 NeuroMetrix (NURO) 6.09 -4.4% 2022-01-19 04:36:11
3 Moderna (MRNA) 180.00 -3.54% 2022-01-19 07:32:23
4 Sabre Corporation (SABR) 9.21 -2.64% 2022-01-19 04:13:57
5 Atlassian (TEAM) 286.69 -2.36% 2022-01-19 04:37:38
6 Cisco (CSCO) 58.53 -2.01% 2022-01-19 07:25:19
7 Infosys Limited (INFY) 25.00 -2% 2022-01-19 07:24:53
8 Amicus Therapeutics (FOLD) 9.27 -1.9% 2022-01-19 07:26:29
9 AB InBev (BUD) 65.63 -1.85% 2022-01-19 04:39:29
10 Fresenius Medical Care AG (FMS) 34.03 -1.76% 2022-01-19 07:24:06

Most Active Premarket Winners today

1. Avery Dennison Corporation (AVY) – Premarket: 14.05%

NYSE ended the session with Avery Dennison Corporation sliding 1.06% to $206.87 on Wednesday while NYSE fell 1.56% to $16,950.91.

Volume

Today’s last reported volume for Avery Dennison Corporation is 530327, 28.87% above its average volume of 411495.

Avery Dennison Corporation’s last close was $206.87, 9.76% under its 52-week high of $229.24.

Avery Dennison Corporation’s Sales

Avery Dennison Corporation’s sales growth is 16.1% for the current quarter and 2.1% for the next. The company’s growth estimates for the ongoing quarter is 7.3% and a drop 4% for the next.

Avery Dennison Corporation’s Revenue

Year-on-year quarterly revenue growth grew by 37.5%, now sitting on 7.87B for the twelve trailing months.

Volatility

Avery Dennison Corporation’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.87%, a negative 0.01%, and a positive 1.18%, respectively.

Avery Dennison Corporation’s highest amplitude of average volatility was 0.87% (last week), 1.37% (last month), and 1.18% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Avery Dennison Corporation’s stock is considered to be overbought (>=80).

Avery Dennison Corporation’s Stock Yearly Top and Bottom Value

Avery Dennison Corporation’s stock is valued at $206.87 at 07:34 EST, below its 52-week high of $229.24 and way higher than its 52-week low of $145.35.

Avery Dennison Corporation’s Moving Average

Avery Dennison Corporation’s worth is under its 50-day moving average of $214.06 and under its 200-day moving average of $214.60.

More news about Avery Dennison Corporation.

2. Bio-Rad (BIO) – Premarket: 12.6%

NYSE ended the session with Bio-Rad dropping 4.53% to $599.80 on Wednesday, after five sequential sessions in a row of losses. NYSE dropped 1.56% to $16,950.91, after three consecutive sessions in a row of losses, on what was an all-around down trend trading session today.

Volume

Today’s last reported volume for Bio-Rad is 208915, 77.67% above its average volume of 117585.

Bio-Rad’s last close was $599.80, 27.97% below its 52-week high of $832.70.

Bio-Rad’s Sales

Bio-Rad’s sales growth is 2.3% for the ongoing quarter and a decline by 7.5% for the next. The company’s growth estimates for the present quarter and the next is a negative 18.7% and a negative 20.9%, respectively.

Bio-Rad’s Revenue

Year-on-year quarterly revenue growth grew by 33.4%, now sitting on 2.88B for the twelve trailing months.

Volatility

Bio-Rad’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.01%, a negative 1.10%, and a positive 1.55%, respectively.

Bio-Rad’s highest amplitude of average volatility was 4.01% (last week), 1.85% (last month), and 1.55% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Bio-Rad’s stock is considered to be overbought (>=80).

Bio-Rad’s Stock Yearly Top and Bottom Value

Bio-Rad’s stock is valued at $599.80 at 07:34 EST, way under its 52-week high of $832.70 and way higher than its 52-week low of $507.22.

Bio-Rad’s Moving Average

Bio-Rad’s value is way below its 50-day moving average of $750.37 and way under its 200-day moving average of $700.87.

More news about Bio-Rad.

3. Broadridge Financial Solutions (BR) – Premarket: 5.82%

NYSE ended the session with Broadridge Financial Solutions sliding 0.09% to $159.92 on Wednesday while NYSE fell 1.56% to $16,950.91.

Volume

Today’s last reported volume for Broadridge Financial Solutions is 691930, 26.94% above its average volume of 545062.

Broadridge Financial Solutions’s last close was $159.92, 13.56% under its 52-week high of $185.00.

Broadridge Financial Solutions’s Revenue

Year-on-year quarterly revenue growth grew by 17.2%, now sitting on 5.17B for the twelve trailing months.

Volatility

Broadridge Financial Solutions’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.86%, a negative 0.40%, and a positive 1.16%, respectively.

Broadridge Financial Solutions’s highest amplitude of average volatility was 2.86% (last week), 1.35% (last month), and 1.16% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Broadridge Financial Solutions’s stock is considered to be overbought (>=80).

Broadridge Financial Solutions’s Stock Yearly Top and Bottom Value

Broadridge Financial Solutions’s stock is valued at $159.92 at 07:34 EST, way under its 52-week high of $185.00 and way above its 52-week low of $137.91.

Broadridge Financial Solutions’s Moving Average

Broadridge Financial Solutions’s worth is below its 50-day moving average of $174.84 and under its 200-day moving average of $165.91.

More news about Broadridge Financial Solutions.

4. Yandex (YNDX) – Premarket: 5.77%

NASDAQ ended the session with Yandex sliding 6.97% to $48.69 on Wednesday while NASDAQ slid 2.6% to $14,506.90.

Volume

Today’s last reported volume for Yandex is 5535170, 198.12% above its average volume of 1856690.

Yandex’s last close was $48.69, 44.11% below its 52-week high of $87.11.

Yandex’s Sales

Yandex’s sales growth is 46.1% for the present quarter and 48.3% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 82.8% and a negative 4.3%, respectively.

Yandex’s Revenue

Year-on-year quarterly revenue growth grew by 96.6%, now sitting on 284.47B for the twelve trailing months.

Volatility

Yandex’s last week, last month’s, and last quarter’s current intraday variation average was a negative 6.62%, a negative 1.17%, and a positive 1.98%, respectively.

Yandex’s highest amplitude of average volatility was 6.62% (last week), 2.67% (last month), and 1.98% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Yandex’s stock is considered to be overbought (>=80).

Yandex’s Stock Yearly Top and Bottom Value

Yandex’s stock is valued at $48.69 at 07:34 EST, way under its 52-week low of $58.91.

Yandex’s Moving Average

Yandex’s value is way below its 50-day moving average of $77.08 and way under its 200-day moving average of $70.92.

More news about Yandex.

5. Quidel (QDEL) – Premarket: 5.16%

NASDAQ ended the session with Quidel sliding 4.2% to $110.06 on Wednesday while NASDAQ slid 2.6% to $14,506.90.

Volume

Today’s last reported volume for Quidel is 740015, 1.35% below its average volume of 750203.

Quidel’s last close was $110.06, 58.47% under its 52-week high of $265.00.

The company’s growth estimates for the ongoing quarter and the next is a negative 84.8% and a negative 87.6%, respectively.

Quidel’s Revenue

Year-on-year quarterly revenue growth declined by 12.5%, now sitting on 1.84B for the twelve trailing months.

Volatility

Quidel’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.28%, a negative 1.46%, and a positive 3.34%, respectively.

Quidel’s highest amplitude of average volatility was 4.28% (last week), 3.46% (last month), and 3.34% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Quidel’s stock is considered to be overbought (>=80).

Quidel’s Stock Yearly Top and Bottom Value

Quidel’s stock is valued at $110.06 at 07:34 EST, way below its 52-week high of $265.00 and above its 52-week low of $103.31.

Quidel’s Moving Average

Quidel’s value is way below its 50-day moving average of $137.22 and way below its 200-day moving average of $130.49.

More news about Quidel.

6. Unilever (UL) – Premarket: 4.5%

NYSE ended the session with Unilever falling 14.44% to $46.45 on Wednesday, after two consecutive sessions in a row of losses. NYSE slid 1.56% to $16,950.91, after three consecutive sessions in a row of losses, on what was an all-around down trend trading session today.

Volume

Today’s last reported volume for Unilever is 37958200, 1325.63% above its average volume of 2662550.

Unilever’s last close was $46.45, 26.33% below its 52-week high of $63.05.

Unilever’s Revenue

Year-on-year quarterly revenue growth grew by 0.3%, now sitting on 50.8B for the twelve trailing months.

Volatility

Unilever’s last week, last month’s, and last quarter’s current intraday variation average was 0.48%, 0.15%, and 0.69%, respectively.

Unilever’s highest amplitude of average volatility was 0.48% (last week), 0.51% (last month), and 0.69% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Unilever’s stock is considered to be oversold (<=20).

Unilever’s Stock Yearly Top and Bottom Value

Unilever’s stock is valued at $46.45 at 07:34 EST, way below its 52-week low of $51.98.

Unilever’s Moving Average

Unilever’s value is way under its 50-day moving average of $53.48 and way under its 200-day moving average of $57.01.

Previous days news about Unilever

  • Glaxosmithkline up 4% after failed $68b unilever bid for consumer health unit. According to MarketWatch on Monday, 17 January, "LONDON – The pharmaceutical giant GlaxoSmithKline said Saturday it has rejected an unsolicited 50 billion-pound ($68.4 billion) bid from Unilever for its consumer healthcare goods unit, a joint venture it controls in a partnership with Pfizer.", "In a brief statement on its website,Unilever said"GSK Consumer Healthcare is a leader in the attractive consumer health space and would be a strong strategic fit as Unilever continues to re-shape its portfolio. "
  • Unilever pursues glaxo and Pfizer consumer health venture. According to The New York Times on Monday, 17 January, "Yet it is unclear that pursuing the GlaxoSmithKline venture would appease Unilever’s investors: Shares in Unilever were down nearly 6 percent in trading on Monday.", "GSK Consumer Health would be a strong strategic fit," Unilever said in a statement, adding that a deal "would also deliver value and certainty for the shareholders of GSK and Pfizer."
  • Glaxosmithkline shares soar after unilever bid for consumer health unit. According to MarketWatch on Monday, 17 January, "Shares of GlaxoSmithKline surged on Monday, while Unilever stock tumbled following a failed $68 billion bid by the latter to acquire the pharmaceutical giant’s consumer healthcare arm.", "Driving the FTSE 100 higher and at the top of the Stoxx Europe 600’s gainer’s list, was GlaxoSmithKline , up 5% after saying Saturday that it has rejected an unsolicited £50 billion ($68.4 billion) Unilever offer for the unit behind painkiller Advil and Sensodyne toothpaste that it jointly owns with Pfizer . "
  • Unilever faces investor hurdle as shadow of mega deals looms. According to Bloomberg Quint on Tuesday, 18 January, "Some investors have already communicated their view by selling Unilever shares for the second day since news broke of its 50 billion-pound ($68 billion) approach to Glaxo, an offer the drugmaker rejected.", "Glaxo’s management will no doubt take note of the lukewarm shareholder response at Unilever as the drugmaker weighs the merits of an uncertain merger versus a spinoff of the business. "
  • Unilever needs $10 billion bump to win glaxo unit, analysts say. According to Bloomberg Quint on Monday, 17 January, "While Unilever could increase its offer to about 55 billion pounds, "we are very doubtful this will be sufficient to persuade the GSK board or GSK investors," analysts at Citigroup Inc. wrote in a report Monday. ", "Analysts who follow Unilever scorned the proposed acquisition, saying it doesn’t make sense and would be too expensive."

More news about Unilever.

7. Cloudflare (NET) – Premarket: 4.13%

NYSE ended the session with Cloudflare falling 6.64% to $93.63 on Wednesday while NYSE fell 1.56% to $16,950.91.

Volume

Today’s last reported volume for Cloudflare is 5653900, 31.54% above its average volume of 4298140.

Cloudflare’s Sales

Cloudflare’s sales growth is 60.6% for the current quarter and 39.6% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 100% and a negative 50%, respectively.

Cloudflare’s Revenue

Year-on-year quarterly revenue growth grew by 52.9%, now sitting on 530.57M for the twelve trailing months.

Volatility

Cloudflare’s last week, last month’s, and last quarter’s current intraday variation average was a negative 9.65%, a negative 1.70%, and a positive 3.84%, respectively.

Cloudflare’s highest amplitude of average volatility was 10.53% (last week), 3.65% (last month), and 3.84% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Cloudflare’s stock is considered to be oversold (<=20).

More news about Cloudflare.

8. Pacific Biosciences of California (PACB) – Premarket: 3.96%

NASDAQ ended the session with Pacific Biosciences of California sliding 10.54% to $11.12 on Wednesday, after five consecutive sessions in a row of losses. NASDAQ slid 2.6% to $14,506.90, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Volume

Today’s last reported volume for Pacific Biosciences of California is 5551330, 98.69% above its average volume of 2793850.

Pacific Biosciences of California’s last close was $11.12, 79.29% below its 52-week high of $53.69.

Pacific Biosciences of California’s Sales

Pacific Biosciences of California’s sales growth is 63.1% for the current quarter and 39.6% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 50% and a negative 164.9%, respectively.

Pacific Biosciences of California’s Revenue

Year-on-year quarterly revenue growth grew by 79.2%, now sitting on 105.83M for the twelve trailing months.

Volatility

Pacific Biosciences of California’s last week, last month’s, and last quarter’s current intraday variation average was a negative 9.15%, a negative 2.75%, and a positive 3.71%, respectively.

Pacific Biosciences of California’s highest amplitude of average volatility was 9.15% (last week), 4.89% (last month), and 3.71% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pacific Biosciences of California’s stock is considered to be overbought (>=80).

Pacific Biosciences of California’s Stock Yearly Top and Bottom Value

Pacific Biosciences of California’s stock is valued at $11.12 at 07:34 EST, way under its 52-week low of $18.63.

Pacific Biosciences of California’s Moving Average

Pacific Biosciences of California’s worth is way under its 50-day moving average of $25.02 and way below its 200-day moving average of $28.55.

More news about Pacific Biosciences of California.

9. Groupon (GRPN) – Premarket: 3.93%

NASDAQ ended the session with Groupon dropping 1.81% to $21.65 on Wednesday while NASDAQ dropped 2.6% to $14,506.90.

Volume

Today’s last reported volume for Groupon is 1006360, 3.97% below its average volume of 1048010.

Groupon’s last close was $21.65, 66.53% under its 52-week high of $64.69.

Groupon’s Sales

Groupon’s sales growth is a negative 29.9% for the current quarter and a decline by 29.7% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 53.3% and a negative 45.1%, respectively.

Groupon’s Revenue

Year-on-year quarterly revenue growth declined by 29.6%, now sitting on 1.09B for the twelve trailing months.

Volatility

Groupon’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.05%, a positive 1.55%, and a positive 4.14%, respectively.

Groupon’s highest amplitude of average volatility was 2.05% (last week), 4.39% (last month), and 4.14% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Groupon’s stock is considered to be overbought (>=80).

Groupon’s Stock Yearly Top and Bottom Value

Groupon’s stock is valued at $21.65 at 07:34 EST, way under its 52-week high of $64.69 and way above its 52-week low of $19.00.

Groupon’s Moving Average

Groupon’s value is under its 50-day moving average of $23.36 and way under its 200-day moving average of $36.51.

More news about Groupon.

10. Canaan (CAN) – Premarket: 3.65%

NASDAQ ended the session with Canaan falling 8.27% to $5.21 on Wednesday while NASDAQ fell 2.6% to $14,506.90.

Volume

Today’s last reported volume for Canaan is 3756630, 24.2% below its average volume of 4956240.

Canaan’s last close was $5.21, 86.68% under its 52-week high of $39.10.

Canaan’s Revenue

Year-on-year quarterly revenue growth grew by 507.3%, now sitting on 447.69M for the twelve trailing months.

Volatility

Canaan’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.79%, a positive 0.23%, and a positive 5.17%, respectively.

Canaan’s highest amplitude of average volatility was 8.37% (last week), 3.95% (last month), and 5.17% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Canaan’s stock is considered to be overbought (>=80).

Canaan’s Stock Yearly Top and Bottom Value

Canaan’s stock is valued at $5.21 at 07:34 EST, way below its 52-week high of $39.10 and way higher than its 52-week low of $3.38.

Canaan’s Moving Average

Canaan’s worth is way under its 50-day moving average of $8.21 and way below its 200-day moving average of $10.66.

More news about Canaan.

Most Active Premarket Losers Today

1. U.S. Bancorp (USB) – Premarket: -4.45%

NYSE ended the session with U.S. Bancorp sliding 1.68% to $62.19 on Wednesday, after three consecutive sessions in a row of losses. NYSE slid 1.56% to $16,950.91, after three consecutive sessions in a row of losses, on what was an all-around bearish trend trading session today.

Volume

Today’s last reported volume for U.S. Bancorp is 7623930, 47.62% above its average volume of 5164540.

U.S. Bancorp’s last close was $62.19, 1.3% below its 52-week high of $63.01.

U.S. Bancorp’s Sales

U.S. Bancorp’s sales growth is 1.4% for the present quarter and 1.3% for the next. The company’s growth estimates for the present quarter and the next is 15.2% and 20%, respectively.

U.S. Bancorp’s Revenue

Year-on-year quarterly revenue growth grew by 46.5%, now sitting on 22.64B for the twelve trailing months.

Volatility

U.S. Bancorp’s last week, last month’s, and last quarter’s current intraday variation average was 0.71%, 0.47%, and 1.22%, respectively.

U.S. Bancorp’s highest amplitude of average volatility was 0.71% (last week), 0.98% (last month), and 1.22% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

U.S. Bancorp’s stock is considered to be oversold (<=20).

U.S. Bancorp’s Stock Yearly Top and Bottom Value

U.S. Bancorp’s stock is valued at $62.19 at 07:34 EST, under its 52-week high of $63.01 and way above its 52-week low of $42.47.

U.S. Bancorp’s Moving Average

U.S. Bancorp’s worth is above its 50-day moving average of $59.90 and above its 200-day moving average of $58.04.

More news about U.S. Bancorp.

2. NeuroMetrix (NURO) – Premarket: -4.4%

NASDAQ ended the session with NeuroMetrix jumping 29.47% to $6.37 on Wednesday while NASDAQ slid 2.6% to $14,506.90.

Volume

Today’s last reported volume for NeuroMetrix is 64053700, 19128.59% above its average volume of 333117.

NeuroMetrix’s last close was $6.37, 83.56% under its 52-week high of $38.75.

NeuroMetrix’s Revenue

Year-on-year quarterly revenue growth declined by 0.8%, now sitting on 7.36M for the twelve trailing months.

Volatility

NeuroMetrix’s last week, last month’s, and last quarter’s current intraday variation average was 3.14%, 0.56%, and 5.36%, respectively.

NeuroMetrix’s highest amplitude of average volatility was 12.95% (last week), 4.96% (last month), and 5.36% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

NeuroMetrix’s stock is considered to be oversold (<=20).

NeuroMetrix’s Stock Yearly Top and Bottom Value

NeuroMetrix’s stock is valued at $6.37 at 07:34 EST, way under its 52-week high of $38.75 and way higher than its 52-week low of $1.90.

NeuroMetrix’s Moving Average

NeuroMetrix’s value is way below its 50-day moving average of $8.84 and below its 200-day moving average of $6.85.

More news about NeuroMetrix.

3. Moderna (MRNA) – Premarket: -3.54%

NASDAQ ended the session with Moderna falling 8.85% to $186.61 on Wednesday while NASDAQ slid 2.6% to $14,506.90.

Volume

Today’s last reported volume for Moderna is 10843700, 6.54% below its average volume of 11602700.

Moderna’s last close was $186.61, 62.49% below its 52-week high of $497.49.

Moderna’s Sales

Moderna’s sales growth is 8216.6% for the current quarter and 1202.8% for the next. The company’s growth estimates for the ongoing quarter and the next is 1694.9% and 1681.2%, respectively.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 6398.5%, now sitting on 7.02B for the twelve trailing months.

Volatility

Moderna’s last week, last month’s, and last quarter’s current intraday variation average was a negative 5.27%, a negative 2.80%, and a positive 4.68%, respectively.

Moderna’s highest amplitude of average volatility was 5.27% (last week), 4.16% (last month), and 4.68% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Moderna’s stock is considered to be overbought (>=80).

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $186.61 at 07:34 EST, way below its 52-week high of $497.49 and way higher than its 52-week low of $102.66.

Moderna’s Moving Average

Moderna’s worth is way under its 50-day moving average of $298.96 and way under its 200-day moving average of $267.83.

More news about Moderna.

4. Sabre Corporation (SABR) – Premarket: -2.64%

NASDAQ ended the session with Sabre Corporation falling 2.17% to $9.46 on Wednesday while NASDAQ fell 2.6% to $14,506.90.

Volume

Today’s last reported volume for Sabre Corporation is 4606680, 40.49% below its average volume of 7742280.

Sabre Corporation’s last close was $9.46, 43.96% below its 52-week high of $16.88.

Sabre Corporation’s Sales

Sabre Corporation’s sales growth is 67.7% for the present quarter and 66.3% for the next. The company’s growth estimates for the current quarter and the next is 35.4% and 42.9%, respectively.

Sabre Corporation’s Revenue

Year-on-year quarterly revenue growth declined by 50.3%, now sitting on 1B for the twelve trailing months.

Volatility

Sabre Corporation’s last week, last month’s, and last quarter’s current intraday variation average was 0.80%, 1.59%, and 3.89%, respectively.

Sabre Corporation’s highest amplitude of average volatility was 2.28% (last week), 2.61% (last month), and 3.89% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Sabre Corporation’s stock is considered to be overbought (>=80).

Sabre Corporation’s Stock Yearly Top and Bottom Value

Sabre Corporation’s stock is valued at $9.46 at 07:34 EST, way under its 52-week high of $16.88 and way above its 52-week low of $7.05.

Sabre Corporation’s Moving Average

Sabre Corporation’s worth is below its 50-day moving average of $9.84 and way under its 200-day moving average of $12.24.

More news about Sabre Corporation.

5. Atlassian (TEAM) – Premarket: -2.36%

NASDAQ ended the session with Atlassian dropping 1.26% to $293.63 on Wednesday while NASDAQ fell 2.6% to $14,506.90.

Volume

Today’s last reported volume for Atlassian is 2251350, 56.04% above its average volume of 1442730.

Atlassian’s last close was $293.63, 39.22% below its 52-week high of $483.13.

The company’s growth estimates for the ongoing quarter and the next is 33.3% and 18.9%, respectively.

Atlassian’s Revenue

Year-on-year quarterly revenue growth grew by 30%, now sitting on 2.09B for the twelve trailing months.

Volatility

Atlassian’s last week, last month’s, and last quarter’s current intraday variation average was a negative 4.10%, a negative 1.36%, and a positive 2.61%, respectively.

Atlassian’s highest amplitude of average volatility was 4.10% (last week), 3.42% (last month), and 2.61% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Atlassian’s stock is considered to be overbought (>=80).

Atlassian’s Stock Yearly Top and Bottom Value

Atlassian’s stock is valued at $293.63 at 07:34 EST, way below its 52-week high of $483.13 and way above its 52-week low of $184.90.

Atlassian’s Moving Average

Atlassian’s value is way under its 50-day moving average of $414.16 and under its 200-day moving average of $318.55.

More news about Atlassian.

6. Cisco (CSCO) – Premarket: -2.01%

NASDAQ ended the session with Cisco sliding 2.66% to $59.73 on Wednesday, after four sequential sessions in a row of losses. NASDAQ slid 2.6% to $14,506.90, following the last session’s downward trend on what was an all-around negative trend exchanging session today.

Volume

Today’s last reported volume for Cisco is 24324100, 14.93% above its average volume of 21163400.

Cisco’s last close was $59.73, 0.9% below its 52-week high of $60.27.

The company’s growth estimates for the present quarter and the next is 5.3% and 3.8%, respectively.

Cisco’s Revenue

Year-on-year quarterly revenue growth grew by 8.1%, now sitting on 50.79B for the twelve trailing months.

Volatility

Cisco’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.32%, a negative 0.01%, and a positive 1.16%, respectively.

Cisco’s highest amplitude of average volatility was 1.32% (last week), 0.87% (last month), and 1.16% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Cisco’s stock is considered to be overbought (>=80).

Cisco’s Stock Yearly Top and Bottom Value

Cisco’s stock is valued at $59.73 at 07:34 EST, below its 52-week high of $60.27 and way higher than its 52-week low of $43.35.

Cisco’s Moving Average

Cisco’s worth is above its 50-day moving average of $55.93 and above its 200-day moving average of $54.36.

More news about Cisco.

7. Infosys Limited (INFY) – Premarket: -2%

NYSE ended the session with Infosys Limited sliding 2.63% to $25.51 on Wednesday, after two successive sessions in a row of losses. NYSE fell 1.56% to $16,950.91, after three sequential sessions in a row of losses, on what was an all-around bearish trend exchanging session today.

Volume

Today’s last reported volume for Infosys Limited is 6868020, 0.38% below its average volume of 6894270.

Infosys Limited’s last close was $25.51, 5.07% above its 52-week high of $24.28.

Infosys Limited’s Revenue

Year-on-year quarterly revenue growth grew by 20.7%, now sitting on 14.91B for the twelve trailing months.

Volatility

Infosys Limited’s last week, last month’s, and last quarter’s current intraday variation average was 0.58%, 0.50%, and 1.36%, respectively.

Infosys Limited’s highest amplitude of average volatility was 1.29% (last week), 1.19% (last month), and 1.36% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Infosys Limited’s stock is considered to be oversold (<=20).

Infosys Limited’s Stock Yearly Top and Bottom Value

Infosys Limited’s stock is valued at $25.51 at 07:34 EST, higher than its 52-week high of $24.28.

Infosys Limited’s Moving Average

Infosys Limited’s value is way above its 50-day moving average of $22.93 and way above its 200-day moving average of $21.12.

More news about Infosys Limited.

8. Amicus Therapeutics (FOLD) – Premarket: -1.9%

NASDAQ ended the session with Amicus Therapeutics dropping 10.26% to $9.45 on Wednesday while NASDAQ slid 2.6% to $14,506.90.

Volume

Today’s last reported volume for Amicus Therapeutics is 2235020, 11.41% below its average volume of 2523150.

Amicus Therapeutics’s last close was $9.45, 62.78% below its 52-week high of $25.39.

The company’s growth estimates for the present quarter and the next is 28% and 33.3%, respectively.

Amicus Therapeutics’s Revenue

Year-on-year quarterly revenue growth grew by 24.2%, now sitting on 281.82M for the twelve trailing months.

Volatility

Amicus Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 2.46%, a negative 0.20%, and a positive 2.78%, respectively.

Amicus Therapeutics’s highest amplitude of average volatility was 6.64% (last week), 4.11% (last month), and 2.78% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Amicus Therapeutics’s stock is considered to be overbought (>=80).

Amicus Therapeutics’s Stock Yearly Top and Bottom Value

Amicus Therapeutics’s stock is valued at $9.45 at 07:34 EST, way under its 52-week high of $25.39 and above its 52-week low of $8.60.

Amicus Therapeutics’s Moving Average

Amicus Therapeutics’s value is way under its 50-day moving average of $11.12 and below its 200-day moving average of $10.29.

More news about Amicus Therapeutics.

9. AB InBev (BUD) – Premarket: -1.85%

NYSE ended the session with AB InBev dropping 1.37% to $66.87 on Wednesday, following the last session’s downward trend. NYSE slid 1.56% to $16,950.91, after three successive sessions in a row of losses, on what was an all-around bearish trend trading session today.

Volume

Today’s last reported volume for AB InBev is 1102160, 43.86% below its average volume of 1963410.

AB InBev’s last close was $66.87, 16.07% below its 52-week high of $79.67.

The company’s growth estimates for the ongoing quarter and the next is a negative 6.3% and a negative 33.3%, respectively.

AB InBev’s Revenue

Year-on-year quarterly revenue growth grew by 31.5%, now sitting on 51.41B for the twelve trailing months.

Volatility

AB InBev’s last week, last month’s, and last quarter’s current intraday variation average was 1.74%, 0.85%, and 1.25%, respectively.

AB InBev’s highest amplitude of average volatility was 2.44% (last week), 1.55% (last month), and 1.25% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

AB InBev’s stock is considered to be oversold (<=20).

AB InBev’s Stock Yearly Top and Bottom Value

AB InBev’s stock is valued at $66.87 at 07:34 EST, way below its 52-week high of $79.67 and way higher than its 52-week low of $54.08.

AB InBev’s Moving Average

AB InBev’s worth is way above its 50-day moving average of $57.59 and higher than its 200-day moving average of $65.81.

More news about AB InBev.

10. Fresenius Medical Care AG (FMS) – Premarket: -1.76%

NYSE ended the session with Fresenius Medical Care AG rising 2.49% to $34.64 on Wednesday, after five consecutive sessions in a row of gains. NYSE slid 1.56% to $16,950.91, after three successive sessions in a row of losses, on what was an all-around bearish trend exchanging session today.

Volume

Today’s last reported volume for Fresenius Medical Care AG is 689772, 77.68% above its average volume of 388208.

Fresenius Medical Care AG’s last close was $34.64, 20.06% under its 52-week high of $43.33.

Fresenius Medical Care AG’s Sales

Fresenius Medical Care AG’s sales growth is a negative 5% for the current quarter and 27.6% for the next. The company’s growth estimates for the ongoing quarter and the next is a negative 26% and a negative 24.7%, respectively.

Fresenius Medical Care AG’s Revenue

Year-on-year quarterly revenue growth declined by 5.2%, now sitting on 17.34B for the twelve trailing months.

Volatility

Fresenius Medical Care AG’s last week, last month’s, and last quarter’s current intraday variation average was 1.26%, 0.48%, and 1.09%, respectively.

Fresenius Medical Care AG’s highest amplitude of average volatility was 1.26% (last week), 1.06% (last month), and 1.09% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Fresenius Medical Care AG’s stock is considered to be oversold (<=20).

Fresenius Medical Care AG’s Stock Yearly Top and Bottom Value

Fresenius Medical Care AG’s stock is valued at $34.64 at 07:34 EST, way under its 52-week high of $43.33 and way higher than its 52-week low of $29.71.

Fresenius Medical Care AG’s Moving Average

Fresenius Medical Care AG’s value is above its 50-day moving average of $33.36 and under its 200-day moving average of $37.59.

More news about Fresenius Medical Care AG.

Stay up to date with our premarket winners and losers daily report

LEAVE A REPLY

Please enter your comment!
Please enter your name here